Xpreza Azacitidine – 100 mg Injection

At a Glance

Generic Name: Azacitidine

Brand Name: Xpreza 100 mg

Strength & Pack Size: 100 mg azacitidine per vial, 1 single-use vial

Dosage Form & Route: Lyophilised powder for subcutaneous injection or intravenous use after reconstitution

Therapeutic Class: Hypomethylating antineoplastic agent (pyrimidine nucleoside analogue)

Primary Indications: Selected myelodysplastic syndromes (MDS), certain AML and chronic myelomonocytic leukaemia (CMML), according to local label

Typical Use in Therapy: Cyclical treatment in specialist haematology units, often as lower-intensity therapy in higher-risk MDS and older AML patients

Mode of Action: Incorporates into RNA/DNA and inhibits DNA methyltransferase, leading to hypomethylation and cytotoxicity in abnormal haematopoietic cells

Key Benefits: Can improve blood counts, delay progression to AML and extend survival in carefully selected patients

Precautions: Requires close monitoring of blood counts, organ function, injection site reactions and infection risk

Storage: Store the vial as per carton instructions, usually refrigerated or below a defined temperature, protected from light until reconstitution

Product Description

Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used in the treatment of certain myelodysplastic syndromes, selected cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia. Each vial provides 100 mg of azacitidine as a lyophilised powder that must be reconstituted with an appropriate diluent before administration. Xpreza 100 mg azacitidine injection is given in cycles, usually as subcutaneous injections or intravenous infusions in a specialist haematology setting.

For many higher-risk MDS patients and some older adults with AML or CMML, azacitidine offers an important treatment option when intensive induction chemotherapy or transplantation is not appropriate or is being deferred. By targeting abnormal marrow cells and altering gene expression patterns, Xpreza 100 mg azacitidine injection can stabilise disease, improve blood counts, reduce transfusion dependence and delay progression to more aggressive leukaemia in a subset of patients. Treatment is typically long-term and requires patience, as responses may take several cycles to become apparent.

Generic Meds Mart supplies Xpreza 100 mg azacitidine injection in original, sealed oncology packaging from licensed manufacturers and authorised distributors. Vials are shipped in neutral outer cartons that do not mention MDS, AML or azacitidine on the exterior, helping protect patient privacy. Inner packaging retains full information, including brand name, strength, batch number and expiry date, so hospital pharmacies can verify the product before preparing each dose. Pricing is presented in USD, supporting transparent planning for repeated azacitidine cycles that may span many months.

Key Uses

Within the framework of local regulatory approvals and guidelines, Xpreza 100 mg azacitidine injection is used for selected myelodysplastic syndromes, including higher-risk subtypes, and for certain presentations of AML and CMML in adults. Typical candidates include patients with significant cytopenias or higher-risk disease features who may not be suitable for intensive induction chemotherapy. Azacitidine treatment is usually delivered as a 7-day or modified 5–7-day cycle repeated every 28 days, although exact schedules vary by protocol and patient tolerance.

The haematology team will decide whether Xpreza 100 mg azacitidine injection is appropriate based on bone marrow findings, cytogenetics, molecular markers, performance status, comorbidities and patient preferences. Azacitidine may be used as a stand-alone disease-modifying therapy, as a bridge to transplant in selected cases or as a long-term management strategy aimed at improving quality of life and delaying disease progression. It is not a “quick fix” and requires regular clinic visits, laboratory monitoring and supportive care.

How Azacitidine Works in Chemotherapy

Azacitidine, the active ingredient in Xpreza 100 mg injection, is a pyrimidine nucleoside analogue with both hypomethylating and cytotoxic properties. Inside cells, azacitidine is incorporated into RNA and, after conversion to its deoxy form, into DNA. When incorporated into DNA, azacitidine inhibits DNA methyltransferase, an enzyme involved in maintaining normal DNA methylation patterns.

By inhibiting DNA methyltransferase, azacitidine leads to hypomethylation of DNA in rapidly dividing abnormal haematopoietic cells. This can reactivate silenced tumour suppressor genes and alter gene expression profiles in a way that reduces the growth advantage of dysplastic or leukaemic cells. At higher doses, azacitidine also has direct cytotoxic effects, causing damage to abnormal cells that are synthesising DNA.

Through these mechanisms, Xpreza 100 mg azacitidine injection can reduce the burden of abnormal clones in the bone marrow and allow healthier progenitor cells to recover. This may translate into improved blood counts, reduced transfusion needs and delayed transformation to overt leukaemia in some patients. However, the same actions also affect normal dividing cells, which is why careful dose selection and monitoring are essential.

Dosage & Administration

Xpreza 100 mg azacitidine injection must only be prescribed and supervised by haematologists experienced in treating MDS, AML and related disorders. The dose is usually calculated based on body surface area (mg/m²) and adjusted according to response, blood counts and tolerability. After reconstitution, azacitidine can be administered subcutaneously into the abdomen, thigh or upper arm, or given intravenously as an infusion, following the product information and local protocols.

Treatment is typically cyclical, with azacitidine given for several consecutive days followed by a rest period. Patients often receive premedication or supportive antiemetics to reduce nausea and vomiting. Blood counts and biochemistry are checked regularly to guide dose delays or reductions and to decide whether growth factors, transfusions or infection prophylaxis are needed. Xpreza 100 mg azacitidine injection should never be self-prepared or self-administered; all handling and administration are undertaken by trained staff in a clinic or hospital.

Precautions

Before starting Xpreza 100 mg azacitidine injection, the haematology team conducts a thorough review of bone marrow status, blood counts, liver and kidney function, infection history and concomitant medicines. Because azacitidine can cause myelosuppression, patients require ongoing monitoring for neutropenia, thrombocytopenia and anaemia, with timely intervention if counts fall.

Injection site reactions are common with subcutaneous dosing, so patients are advised about rotating injection sites and reporting severe redness, pain or nodules. Nausea, vomiting and diarrhoea are frequent early in treatment, making antiemetics and hydration protocols important. Azacitidine is contraindicated in pregnancy and breastfeeding, and effective contraception is usually recommended during treatment and for a period afterwards. Decisions about continuing, interrupting or stopping Xpreza 100 mg azacitidine injection depend on response, tolerance and evolving clinical status.

Azacitidine Side Effects

Common side effects

Common azacitidine side effects with Xpreza 100 mg injection include low blood counts (neutropenia, thrombocytopenia and anaemia), injection site redness or bruising, nausea, vomiting, diarrhoea or constipation, loss of appetite, fatigue, mild fever, and general weakness. Some patients experience transient kidney or liver test abnormalities, mild headache or injection site pain. These effects are often most noticeable during early cycles and may stabilise or become more manageable as the team refines dosing and supportive care.

Many of these common azacitidine side effects can be addressed with antiemetics, careful hydration, local skin care, growth factor support, transfusions and temporary dose adjustments or delays. Patients are encouraged to keep a symptom diary and bring concerns to clinic visits so that the haematology team can optimise supportive measures.

Serious side effects

Serious azacitidine adverse effects require prompt medical attention. These can include severe or prolonged neutropenia with high risk of infection, sepsis, severe thrombocytopenia with active bleeding, severe gastrointestinal toxicity with dehydration, acute kidney or liver dysfunction, hypersensitivity reactions and, rarely, serious local reactions or tissue damage at injection sites.

Patients should be instructed to contact their treatment centre or emergency services immediately if they develop high fever, chills, shortness of breath, chest pain, uncontrolled vomiting or diarrhoea, black or bloody stools, unusual bleeding or bruising, marked decrease in urine output, confusion or any other alarming symptom. The medical team may need to hold further doses of Xpreza 100 mg azacitidine injection, adjust the regimen or intensify supportive care depending on the severity and suspected cause.

Storage

Xpreza 100 mg azacitidine injection vials should be stored as indicated on the product carton and in the package leaflet, which may include refrigerated storage or a controlled room temperature range. Vials must be kept in the original outer carton to protect from light and should remain out of the reach of children. Reconstituted suspensions or solutions have limited stability and must be prepared and used within the timeframes specified by the manufacturer and local cytotoxic preparation guidelines. Any unused product and materials that have been in contact with azacitidine must be discarded as cytotoxic waste.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on structured access to essential haematology and oncology medicines such as Xpreza 100 mg azacitidine injection. We source only from licensed manufacturers and authorised distributors that comply with Good Manufacturing Practice and provide full batch traceability. Each vial of Xpreza 100 mg is supplied in sealed original packaging, allowing hospital pharmacies and clinic staff to verify brand, strength, batch number and expiry before preparation.

By listing Xpreza 100 mg azacitidine injection in USD, Generic Meds Mart helps patients and centres plan the cost of repeated treatment cycles. Neutral shipping cartons preserve confidentiality during international delivery, while tracking (where available) allows coordination of shipments with clinic appointments and laboratory monitoring. Our role is to support access and logistics; all decisions about whether, when and how to use azacitidine remain entirely with the treating haematology team.

Order Now

Xpreza 100 mg azacitidine injection is a specialised medicine for MDS, AML and CMML that must never be used without a clear plan from an experienced haematologist. Before arranging supply through Generic Meds Mart, the team should confirm diagnosis, risk category, treatment goals, suitability for azacitidine, proposed dosing schedule and expected duration of therapy. They should also ensure that appropriate monitoring, transfusion support and emergency care pathways are in place.

Once this framework is agreed, the centre or designated purchaser can estimate how many vials of Xpreza 100 mg are needed for the first several cycles. They can then select the corresponding quantity on Generic Meds Mart, add it to the cart and complete secure checkout in USD. Medicines are dispatched in discreet outer packaging with full original labelling inside. Patients and caregivers should never attempt to reconstitute or inject azacitidine themselves unless explicitly trained and authorised by their team, and any new or severe symptoms should be reported promptly for evaluation.

FAQ about Xpreza (Azacitidine)

Q1: What is Xpreza 100 mg used for?
Xpreza 100 mg contains azacitidine, a hypomethylating antineoplastic agent used under haematology supervision in selected myelodysplastic syndromes, certain cases of acute myeloid leukaemia and chronic myelomonocytic leukaemia, according to local product information and guidelines.

Q2: Is Xpreza 100 mg given as an injection or a tablet?
Xpreza 100 mg is supplied as a vial of lyophilised powder that is reconstituted and given as a subcutaneous injection or intravenous dose, depending on protocol. It is not an oral tablet and should only be administered by trained healthcare professionals following the official instructions.

Q3: How long will I need to stay on azacitidine?
Many patients receive Xpreza 100 mg azacitidine injection for multiple cycles, often at least six or more, before treatment is fully evaluated. If there is clinical benefit and side effects remain manageable, therapy may continue for an extended period. The haematology team will review response, blood counts and quality of life regularly to decide how long to maintain azacitidine.

Q4: Can Xpreza 100 mg cure my MDS or AML?
Azacitidine is generally considered a disease-modifying treatment rather than a direct cure for most patients. It can improve blood counts, reduce transfusion needs, delay progression and extend survival in selected cases. In some patients it may be used as a bridge to transplantation, which offers the potential for long-term remission. Your team will explain realistic goals for your individual situation.

Q5: What monitoring is needed during treatment with Xpreza 100 mg?
Patients on Xpreza 100 mg azacitidine injection need regular full blood counts, kidney and liver function tests, clinical assessments for infection and bleeding, and review of injection sites and gastrointestinal symptoms. These checks help the team adjust doses, time cycles appropriately and provide supportive care to manage side effects safely.

Kabanat 60 mg / 5 mL Cabazitaxel Injection (1 vial)

At a Glance

Generic Name: Cabazitaxel

Brand Name: Kabanat

Strength & Pack Size: 60 mg/5 mL per vial; 1 vial

Dosage Form & Route: Injection concentrate/solution for IV infusion after dilution (hospital administration)

Therapeutic Class: Taxane antineoplastic, microtubule inhibitor (cytotoxic chemotherapy)

Primary Indication: Metastatic castration-resistant prostate cancer (mCRPC), typically after docetaxel-based therapy when a specialist selects cabazitaxel

Usual Adult Dose: Given as an IV infusion in cycles (often every 3 weeks) with supportive medicines; exact dose and duration are defined by your oncology specialist

Prescription Status: Prescription-only / hospital-use medicine

Storage: Store as directed on the carton; protect from light and keep out of reach of children

Product Description

Kabanat 60 mg / 5 mL contains cabazitaxel, a taxane chemotherapy medicine used in adults with metastatic castration-resistant prostate cancer (mCRPC) when a treating oncology specialist determines that cabazitaxel is appropriate after prior therapy. This presentation is supplied as one vial intended for preparation and intravenous infusion by trained healthcare professionals in a clinic or hospital setting. Cabazitaxel is not a self-injected medicine and should not be handled or administered outside controlled clinical procedures.

In mCRPC, treatment is chosen based on prior lines of therapy, performance status, blood counts, liver function, symptom burden, and potential medicine interactions. Cabazitaxel may be selected when ongoing disease control is needed and your specialist considers a taxane-based approach suitable. Your oncology team also plans supportive medicines and monitoring to reduce risk and to keep treatment on schedule.

Generic Meds Mart supplies Kabanat cabazitaxel injection in original packaging sourced through licensed channels. The vial and carton typically show the brand name, strength, active ingredient, batch number, and expiry date so a clinic pharmacy can verify the product on receipt. Orders are processed with secure checkout in USD and shipped in discreet outer packaging; international delivery options help patients and clinics coordinate supply with infusion appointments.

Key Uses

Kabanat cabazitaxel injection is used for adults with metastatic castration-resistant prostate cancer in specialist-led treatment plans. This is an advanced form of prostate cancer that continues to progress despite androgen-deprivation therapy, and it often requires sequencing of multiple systemic treatments over time.

Cabazitaxel is administered as an IV infusion in cycles, and the goals of therapy are defined by your specialists, such as symptom control, slowing progression, or maintaining quality of life. If you need to order cabazitaxel injection online, make sure your clinic has a clear plan for infusion scheduling, blood-test monitoring, and supportive medicines.

How Cabazitaxel Works in Chemotherapy

Cabazitaxel belongs to the taxane class of anticancer medicines and works by interfering with microtubules, which are essential structures that help cells divide. By stabilising microtubules and preventing their normal function, cabazitaxel disrupts cell division and can lead to cell death in rapidly dividing cancer cells.

Because taxanes can also affect some normal rapidly dividing cells, monitoring remains essential. Your oncology team evaluates benefit versus risk over time and may adjust the plan based on response, tolerance, laboratory results, and other treatments you are receiving.

Dosage & Administration

Kabanat is prepared and administered by trained healthcare professionals as an intravenous infusion. The cabazitaxel dose is typically calculated by the oncology team using body surface area and adjusted based on blood counts, liver function, prior toxicities, and clinical response. Treatment is usually given in cycles with rest periods, and your specialist decides the number of cycles and whether dose reductions or delays are needed.

Cabazitaxel infusion requires careful preparation and dilution according to the product information used in your treatment centre. Premedication is commonly used to reduce the risk of hypersensitivity reactions, and additional supportive medicines may be prescribed to reduce infection risk or manage nausea and bowel symptoms. Never attempt to self-administer cabazitaxel or change infusion timing without the instruction of your treating oncology team.

If you are comparing options or checking cabazitaxel price, do not base decisions only on cost. Your clinic must confirm the correct strength, vial size, and the number of vials required per cycle for the prescribed dose, as well as the handling requirements for cytotoxic medicines.

Precautions

Cabazitaxel can cause severe neutropenia and other blood count changes, increasing the risk of serious infection and bleeding. Regular blood counts are required before each cycle. Fever, chills, sore throat, new cough, burning when urinating, or any signs of infection should be treated as urgent during chemotherapy and reported immediately.

Severe diarrhoea, dehydration, abdominal pain, or persistent vomiting can occur and may require prompt medical care. Infusion reactions are also possible, so patients are monitored during treatment. Tell your team about all medicines you take, including anticoagulants, steroids, antibiotics, and supplements, because interactions and overlapping toxicities can affect safety. Cabazitaxel can harm an unborn baby, so contraception planning should be discussed with your oncology team.

Cabazitaxel Side Effects

Common side effects

Common cabazitaxel side effects may include low blood counts, fatigue, nausea, decreased appetite, taste changes, diarrhoea or constipation, mild abdominal discomfort, hair thinning or loss, muscle or joint aches, and mouth soreness. Many effects can be managed with supportive medicines and close follow-up, but persistent or worsening symptoms should be discussed with your oncology team.

Serious side effects

Serious side effects require urgent medical attention and may include febrile neutropenia, sepsis, severe infections, significant bleeding, severe diarrhoea with dehydration, and severe allergic reactions. If you experience high fever, uncontrolled diarrhoea, black stools, severe abdominal pain, chest pain, shortness of breath, confusion, fainting, or rapidly worsening weakness, seek urgent care and tell clinicians you are receiving cabazitaxel.

Storage

Store Kabanat 60 mg / 5 mL in the original carton under the conditions stated on the label, protected from light. Handling, dilution, and disposal are typically managed by hospital or clinic pharmacies under cytotoxic safety procedures. Do not use the vial after the expiry date.

Why Buy from Generic Meds Mart

Generic Meds Mart supports access and logistics for specialist oncology medicines such as Kabanat cabazitaxel injection. We supply products in original packaging with batch and expiry details visible to support verification by pharmacies and infusion centres. Pricing is displayed in USD, orders are processed through secure checkout, and shipments use discreet outer packaging with worldwide delivery options to help coordinate supply with infusion appointments.

Order Now

Before you buy Kabanat 60 mg online from Generic Meds Mart, you should have a confirmed diagnosis of metastatic castration-resistant prostate cancer and a cabazitaxel-based treatment plan agreed with your oncology team. Your clinic will advise on required blood tests, supportive medicines, and how many vials are needed per cycle based on the prescribed dose and schedule. Once the plan is confirmed, select Kabanat 60 mg / 5 mL Injection (1 vial), add it to your cart, and complete secure checkout in USD.

Do not start cabazitaxel without specialist supervision and do not change infusion timing or supportive medicines on your own. If you develop fever, severe diarrhoea, signs of infection, uncontrolled vomiting, chest pain, or rapidly worsening weakness, seek urgent medical care and inform clinicians that you are receiving cabazitaxel.

FAQ about Kabanat (Cabazitaxel)

Q1: What is Kabanat 60 mg used for?

Kabanat contains cabazitaxel, a taxane chemotherapy medicine used in adults with metastatic castration-resistant prostate cancer (mCRPC), often after prior docetaxel-based treatment, when prescribed by an oncology specialist.

Q2: Is Kabanat an oral medicine or an infusion?

Kabanat is supplied as an injection vial for preparation and intravenous infusion by trained healthcare professionals. It is not a capsule or tablet and is not intended for self-administration at home.

Q3: How often is cabazitaxel usually given?

Cabazitaxel is typically given in cycles with rest periods, often every 3 weeks, but the exact schedule, dose, and number of cycles are defined by your oncology team based on your regimen and monitoring results.

Q4: What are the most important warnings during treatment?

Key warnings include risk of severe neutropenia and infection, severe diarrhoea and dehydration, and infusion reactions. Fever, chills, severe diarrhoea, or any sudden worsening symptoms should be reported urgently.

Q5: What monitoring is usually needed while receiving cabazitaxel?

Monitoring commonly includes blood counts before each cycle and clinical checks for infection symptoms, bowel side effects, hydration status, and overall tolerance. Your oncology team sets the monitoring schedule and supportive medicines.

Azadine 100 mg Azacitidine Injection (1 vial)

At a Glance

Generic Name: Azacitidine

Brand Name: Azadine 100 mg

Strength & Pack Size: 100 mg azacitidine, 1 vial of lyophilised powder for injection

Dosage Form & Route: Powder for suspension or solution, for subcutaneous (SC) or intravenous (IV) administration after reconstitution

Therapeutic Class: Hypomethylating antineoplastic agent

Primary Indications: Myelodysplastic syndromes (MDS) and selected acute myeloid leukemia (AML) cases, as per local label

Typical Patient Setting: Adults treated in specialist haematology–oncology centres with access to intensive monitoring

Mode of Action: Inhibits DNA methyltransferase, leading to hypomethylation and direct cytotoxic effects on abnormal marrow cells

Key Benefits: Proven improvement in blood counts and survival in higher-risk MDS and certain AML populations when used appropriately

Precautions: Requires close monitoring of blood counts, organ function and injection site reactions; hospital infrastructure recommended

Storage: Store in the original carton at the temperature stated in the leaflet; protect from light and follow reconstitution stability guidance

Product Description

Azadine 100 mg azacitidine injection is a hypomethylating agent used in the treatment of myelodysplastic syndromes (MDS) and in selected acute myeloid leukemia (AML) settings according to local prescribing information and specialist guidelines. Azacitidine targets abnormal bone marrow cells by interfering with DNA methylation and exerting direct cytotoxic effects, helping to restore more normal blood cell production over time.

Each vial of Azadine 100 mg contains 100 mg of azacitidine as a sterile lyophilised powder that must be reconstituted with an appropriate diluent before administration. Depending on local protocols, the reconstituted suspension or solution is given either subcutaneously or intravenously in repeated treatment cycles. Because of the risks of myelosuppression, infection and other serious side effects, Azadine 100 mg injection is used under the supervision of experienced haematologists and oncologists in facilities that can provide supportive care and regular monitoring.

When you buy Azadine 100 mg online from Generic Meds Mart, you receive original manufacturer vials in sealed cartons with clearly visible batch numbers and expiry dates. Products are sourced only from licensed distributors experienced in oncology and haematology supply chains. Outer shipping boxes are neutral, without visible references to MDS, AML or chemotherapy, to protect patient privacy, while maintaining complete traceability for pharmacies and clinics. Our mission is to support access and logistics; all treatment decisions remain with your specialist team.

Key Uses

Azadine 100 mg azacitidine injection is used in adults for myelodysplastic syndromes (MDS) and certain acute myeloid leukemia (AML) presentations, as defined in regional labels and guidelines. Typical indications include:

• Myelodysplastic syndromes (MDS), including subtypes with excess blasts, where disease-modifying hypomethylating therapy is indicated.
• Selected cases of AML, particularly those evolving from MDS or with lower blast percentages, where azacitidine-based regimens are supported by local protocols.

The choice to use Azadine 100 mg is individualized and considers patient age, performance status, cytogenetic and molecular risk, comorbidities and eligibility for alternative options such as intensive chemotherapy or stem cell transplantation. Azacitidine injection is often chosen for higher-risk MDS or for patients in whom traditional intensive regimens would be inappropriate or poorly tolerated.

How Azacitidine Works in Chemotherapy

Azacitidine, the active ingredient in Azadine 100 mg, is a cytidine analogue that exerts its antineoplastic effects through dual mechanisms. At lower concentrations, azacitidine incorporates into RNA and DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This hypomethylation can reactivate silenced tumour suppressor genes and modify abnormal gene expression patterns in dysplastic bone marrow cells.

At higher concentrations, azacitidine has direct cytotoxic effects on rapidly dividing cells, leading to cell death. In the context of myelodysplastic syndromes and certain AML subtypes, these mechanisms help reduce the burden of abnormal progenitor cells and support recovery of more normal haematopoiesis over repeated treatment cycles. Response to azacitidine therapy builds gradually, so clinicians often continue treatment for multiple cycles before judging benefit, provided tolerance and safety profiles remain acceptable.

Dosage & Administration

The dosing of Azadine 100 mg azacitidine injection is defined by body surface area and local prescribing information. A commonly used regimen in MDS involves administration of azacitidine for a set number of days in a 28-day cycle, given either subcutaneously or intravenously. Regimens, exact dose in mg/m², route and number of treatment cycles may vary based on label, institutional practice and individual patient factors.

Azadine vials must be reconstituted with the recommended diluent, using aseptic technique, and the resulting suspension or solution is administered within defined stability periods. Administration is performed only by trained healthcare professionals. Blood counts, kidney and liver function, as well as clinical status, are closely monitored before and during each cycle. Dose delays, reductions or interruptions may be necessary in response to myelosuppression, infections or other toxicities. Patients should never attempt to reconstitute or administer azacitidine themselves.

Precautions

Before starting Azadine 100 mg, your haematology team will review your full medical history, including prior treatments, performance status, infection risk, kidney and liver function and concurrent medications. Baseline blood counts and biochemistry help guide eligibility and dosing. Because azacitidine can cause profound myelosuppression, the risk of infections and bleeding must be considered, and prophylactic or early-intervention strategies may be used where appropriate.

Patients may be counselled about the potential need for blood or platelet transfusions, antimicrobial prophylaxis, hospital admission during infections and frequent laboratory monitoring. Azacitidine injection is not suitable for all patients; those with severe organ dysfunction or uncontrolled infections may require stabilisation before treatment or alternative approaches. Women and men of childbearing potential are usually advised to use effective contraception during treatment and for a period afterwards, as azacitidine can harm a developing baby. Breastfeeding is generally not recommended during therapy.

Azacitidine Side Effects

Common side effects

Common azacitidine side effects during Azadine 100 mg therapy include nausea, vomiting, diarrhoea or constipation, loss of appetite, fatigue, weakness, injection site reactions (for subcutaneous administration), mild rash, headache and low-grade fever. Haematologic side effects are very frequent and may involve reduced white cells, red cells and platelets, leading to higher risk of infections, anaemia and bruising or bleeding.

Many of these reactions can be managed with supportive medicines such as antiemetics, analgesics, topical measures for injection sites, growth factors in selected cases, transfusions and dose adjustments or cycle delays. Patients are encouraged to report any new or worsening symptoms promptly so that the medical team can intervene early and adjust treatment if needed.

Serious side effects

Serious azacitidine adverse effects require urgent medical attention and may include severe neutropenia with life-threatening infections, sepsis, severe thrombocytopenia with major bleeding, serious allergic reactions, pronounced liver or kidney injury, severe gastrointestinal events and rare but significant cardiac complications.

Warning signs to watch for include high or persistent fever, chills, severe sore throat, shortness of breath, chest pain, confusion, uncontrolled bleeding or bruising, black stools, vomiting blood, severe abdominal pain, markedly reduced urine output, yellowing of the skin or eyes or sudden swelling. If any of these occur during treatment with Azadine 100 mg azacitidine injection, emergency medical help should be sought immediately and healthcare professionals informed that you are receiving a hypomethylating agent.

Storage

Azadine 100 mg vials should be stored in their original cartons at the temperature specified in the product leaflet, protected from light and kept out of reach of children. They should not be frozen. After reconstitution, the azacitidine suspension or solution has a limited stability window and specific storage conditions, which must be followed closely by the pharmacy and infusion or day-care unit. Unused reconstituted product and materials used for preparation and administration must be disposed of as cytotoxic waste according to local regulations.

Why Buy from Generic Meds Mart

Generic Meds Mart is focused on improving access to essential haematology–oncology therapies such as Azadine 100 mg azacitidine injection, particularly in regions where availability and pricing can be barriers. We collaborate only with licensed manufacturers and authorised distributors who follow recognised quality and safety standards and provide full batch traceability. By supplying Azadine 100 mg in sealed original packaging, we support hospital pharmacies and clinics in verifying product authenticity and integrity.

Orders are processed in USD using secure online payment systems. Shipments are prepared in neutral outer packaging without visible oncology references, with the option for tracked delivery where available. This helps centres plan treatment cycles and ensure that azacitidine vials arrive in time for scheduled therapy. Our role is purely logistical; decisions about whether azacitidine is suitable, how many cycles to give and how to manage side effects are entirely the responsibility of the treating haematology–oncology team.

Order Now

Before arranging to buy Azadine 100 mg azacitidine injection online from Generic Meds Mart, you should have a confirmed diagnosis of myelodysplastic syndrome or AML where azacitidine is recommended, and a clear treatment plan from your specialist detailing dose, route, schedule and monitoring requirements. Your team will explain how azacitidine therapy fits into your overall care, expected benefits, potential risks and the importance of regular follow-up.

Once this plan is in place, your clinic or you, in agreement with your doctors, can determine how many Azadine 100 mg vials are needed per cycle and for the planned number of cycles. After you select the required quantity, you can complete secure checkout in USD. You should never start, stop or modify azacitidine treatment on your own; any changes must be guided by your haematology–oncology team. Generic Meds Mart exists to provide a discreet, reliable supply channel for Azadine 100 mg azacitidine injection, while all complex clinical decisions remain with your specialists.

FAQ about Azadine (Azacitidine)

Q1: What conditions is Azadine 100 mg used to treat?

Azadine 100 mg contains azacitidine, a hypomethylating agent used for myelodysplastic syndromes (MDS) and selected acute myeloid leukemia (AML) cases in adults, according to local prescribing information and specialist guidelines.

Q2: Is Azadine 100 mg an infusion or an injection under the skin?

Azadine 100 mg azacitidine can be given as a subcutaneous injection or as an intravenous infusion, depending on local protocols and patient factors. The powder in the vial is reconstituted by healthcare professionals, who then administer it using the route and schedule defined in your treatment plan.

Q3: How many treatment cycles of azacitidine will I need?

The number of azacitidine cycles varies between patients. Many people require multiple cycles, often at least six, before a full assessment of response is made, provided side effects remain manageable. Your haematology team will explain how many cycles they recommend and how they will evaluate benefit over time.

Q4: Will I need to stay in hospital for Azadine treatment?

Some patients receive Azadine 100 mg as day-care treatment, while others may need hospital admission, especially early in therapy or if complications arise. Decisions about inpatient versus outpatient management depend on your overall health, blood counts, infection risk and local practice.

Q5: Can Azadine 100 mg cure my disease?

In some patients, azacitidine can lead to durable remissions and significantly improved survival, but not everyone achieves a complete cure with hypomethylating therapy alone. For some individuals, Azadine 100 mg may serve as a bridge to other treatments such as stem cell transplantation. Your haematologist is best placed to discuss realistic goals of therapy in your specific situation.

Q6: Is Azadine 100 mg the same as Vidaza (Generic Vidaza)?
Azadine 100 mg is Generic Vidaza — it contains the same active ingredient (azacitidine) as Vidaza. It’s used for the same purpose at the same strength, while differences may be in manufacturer, inactive ingredients (excipients), vial appearance, and packaging. If you’re switching between products, confirm the substitution with a qualified healthcare professional.

Alkacel 50 mg/1 mL Melphalan Injection Ampoule

At a Glance

Generic Name: Melphalan

Brand Name: Alkacel

Strength & Pack Size: 50 mg/1 mL single-use melphalan injection ampoule

Dosage Form & Route: Cytotoxic concentrate for IV infusion after dilution, prepared in hospital

Therapeutic Class: Alkylating agent chemotherapy

Primary Indications: Multiple myeloma and selected conditioning regimens for haematopoietic stem cell transplantation, as per local label

Typical Use in Therapy: Used in specialist oncology and haematology protocols alongside other chemotherapies and supportive medicines

Prescription Status: Prescription-only cytotoxic medicine for use in hospitals or accredited infusion centres

Storage: Store in a refrigerator at 2–8 °C in the original carton; protect from light and follow cytotoxic handling procedures

Product Description

Alkacel 50 mg/1 mL is a melphalan-based injectable chemotherapy supplied as a single-use ampoule intended for dilution and intravenous infusion in controlled hospital settings. Melphalan is an alkylating agent that has played a central role in multiple myeloma treatment and in certain high-dose conditioning regimens prior to haematopoietic stem cell transplantation. Each Alkacel ampoule contains 50 mg melphalan in 1 mL, which must be diluted according to the product information and institutional protocols before being given to the patient.

Because melphalan is highly active against dividing cells and unstable in solution, Alkacel must only be prepared by trained pharmacists or chemotherapy nurses using aseptic technique in a designated preparation area. The diluted infusion is administered via a central line or peripheral vein over a defined period, with careful monitoring of vital signs and laboratory parameters. Alkacel injection is never self-administered and is not suitable for home use.

Generic Meds Mart supplies Alkacel 50 mg/1 mL ampoules in original manufacturer cartons obtained from licensed oncology distributors. Each carton and ampoule is labelled with the brand name, generic name, strength, batch number, expiry date and storage conditions so that hospital pharmacy teams can verify every unit before it enters chemotherapy preparation workflows. Parcels are shipped in plain outer packaging without visible references to myeloma, transplantation or chemotherapy, supporting patient privacy while maintaining full traceability of oncologic medicines. Our role is limited to medicine access and logistics; all treatment decisions remain with your specialist team.

Key Uses

Alkacel melphalan injection is most commonly used in multiple myeloma. At conventional doses, melphalan may form part of systemic treatment regimens, often in combination with other chemotherapies, immunomodulatory agents or corticosteroids. At high doses, melphalan is frequently used as a conditioning agent before autologous stem cell transplantation in eligible patients, with the aim of achieving deeper remission in relapsed or newly diagnosed myeloma.

In some centres and according to local approvals, melphalan may also be used in selected other haematologic malignancies or conditioning protocols. The exact indication, dose and schedule for Alkacel are always defined by experienced haematologists or oncologists who are familiar with melphalan-containing regimens and with the supportive care required during treatment.

How Melphalan Works in Chemotherapy

Melphalan, the active ingredient in Alkacel, is a bifunctional alkylating agent related to nitrogen mustard. It acts by forming covalent bonds with DNA, leading to cross-linking of DNA strands and interference with replication and transcription. This damage is particularly harmful to rapidly dividing cells such as malignant plasma cells in multiple myeloma, which rely on continuous DNA synthesis to survive and proliferate.

By creating DNA cross-links and associated strand breaks, melphalan triggers cell-cycle arrest and programmed cell death in susceptible tumour cells. Normal tissues with high turnover, such as bone marrow and gastrointestinal mucosa, are also affected to some degree, which explains many of the treatment-limiting toxicities associated with melphalan. In the high-dose transplant setting, melphalan is used to deliver a powerful cytotoxic hit to residual myeloma cells, followed by infusion of stem cells to re-establish healthy blood formation.

Dosage & Administration

Dosing of Alkacel melphalan injection is highly individualised and must always follow an approved protocol under specialist supervision. Regimens may use body-surface-area–based dosing expressed in mg/m², fixed mg doses or high-dose schedules in the transplant setting. The same 50 mg/1 mL ampoule can therefore be used in very different ways depending on whether the goal is systemic disease control or intensive conditioning.

Alkacel ampoules are drawn up and diluted with the specified diluent by trained staff in a pharmacy clean room or chemotherapy preparation area. Because melphalan solutions are not stable for long, the prepared infusion is typically used promptly within the time limits given in the product information. Patients receive the infusion intravenously, usually over a set period, with regular monitoring of blood pressure, heart rate, temperature and other clinical parameters. Concomitant antiemetics, hydration and other supportive medicines are often used to help manage side effects. Patients should never attempt to prepare or administer melphalan themselves.

Precautions

Before starting Alkacel, your medical team will carefully review your overall health, cardiac and renal function, liver status, pulmonary history and previous exposure to chemotherapy and radiotherapy. Melphalan can cause profound bone marrow suppression, so baseline blood counts and frequent monitoring during and after treatment are essential. Existing infections must be addressed, and prophylactic antimicrobials may be recommended in high-risk regimens.

Melphalan has mutagenic and potentially carcinogenic properties, and prior or concomitant therapies may influence the long-term risk of therapy-related myeloid neoplasms. Fertility may be affected, particularly with high-dose melphalan, and fertility preservation options are often discussed before treatment where feasible. Effective contraception is usually required during and for a period after melphalan therapy; Alkacel is generally avoided during pregnancy and breastfeeding unless the potential benefit clearly outweighs the risks and this is documented by the treating team.

Melphalan Side Effects

Common side effects

Common melphalan side effects include bone marrow suppression with neutropenia, anaemia and thrombocytopenia, leading to increased susceptibility to infections, fatigue, shortness of breath and easy bruising or bleeding. Nausea, vomiting, diarrhoea, abdominal discomfort and mucositis or mouth sores may occur, especially at higher doses. Many patients experience hair thinning or hair loss, temporary changes in taste and appetite loss during treatment. Transient increases in liver enzymes or mild changes in kidney function may also be observed and are monitored through regular blood tests.

Serious side effects

Serious melphalan adverse effects require urgent medical attention and may necessitate dose reduction, treatment delay or discontinuation. These include severe infections or sepsis, marked thrombocytopenia with significant bleeding, prolonged or profound neutropenia, serious gastrointestinal toxicity, pulmonary complications and, rarely, severe hepatic or renal impairment. Over the longer term, there is a recognised risk of therapy-related myelodysplastic syndromes or acute leukaemias in some patients exposed to alkylating agents such as melphalan, particularly when combined with other intensive treatments. Any high fever, uncontrolled bleeding, chest pain, sudden shortness of breath, confusion, severe abdominal pain or other alarming symptom during or after Alkacel therapy should be reported immediately to your haematology team or emergency services.

Storage

Unopened Alkacel 50 mg/1 mL ampoules should be stored in a refrigerator at 2–8 °C in their original cartons, protected from light and moisture, and handled according to local cytotoxic medicine guidelines. Prepared melphalan infusions have limited stability and must be used or discarded within the time frame specified in the product information and institutional protocols. Patients are not expected to store or handle Alkacel ampoules or prepared infusions at home; all storage, preparation and disposal are managed by hospital or infusion centre staff using appropriate cytotoxic waste procedures.

Why Buy from Generic Meds Mart

Generic Meds Mart focuses on helping patients and clinics access essential oncology medicines such as Alkacel melphalan injection in regions where local supply or cost can be challenging. We work only with licensed manufacturers and authorised distributors that follow recognised quality standards and maintain full batch and expiry traceability. By supplying Alkacel 50 mg/1 mL ampoules in sealed original cartons, we support hospital pharmacies in verifying that each unit matches the melphalan brand and strength specified in their treatment protocols.

All Alkacel orders placed through Generic Meds Mart are processed in USD via secure online checkout. Parcels are shipped in neutral outer packaging with no visible references to multiple myeloma, transplantation or chemotherapy. Where available, tracked shipping options help oncology teams plan treatment dates and transplant schedules around confirmed delivery windows, reducing the risk of delays caused by supply interruptions. Our role is to support timely and discreet access to melphalan; decisions about whether Alkacel is appropriate and how it should be used remain entirely with your specialists.

Order Now

Before you order Alkacel 50 mg/1 mL online from Generic Meds Mart, you should already have a confirmed diagnosis and a written treatment plan from your haematologist or oncologist that specifically includes melphalan, the intended dose and the number of cycles or conditioning schedule. Your treatment centre will calculate how many Alkacel ampoules are needed and will usually coordinate delivery so that pharmacy and chemotherapy units receive the medicine in advance of planned treatment dates.

You should never attempt to self-prescribe melphalan, modify the dose on your own or substitute between different melphalan products without direct guidance from your healthcare team. If you experience new or worsening symptoms such as high fever, uncontrolled bleeding, persistent vomiting, chest pain, sudden shortness of breath or marked weakness during or after melphalan-based therapy, seek urgent medical attention. Generic Meds Mart exists to support reliable, discreet supply of Alkacel melphalan injection, while the complex clinical management of your cancer remains with your specialist team.

FAQ about Alkacel (Melphalan)

Q1: What conditions is Alkacel used to treat?

Alkacel contains melphalan, an alkylating agent used mainly in multiple myeloma and certain high-dose conditioning regimens before haematopoietic stem cell transplantation. In some centres, melphalan may also be used in selected other haematologic indications according to local approvals and guidelines.

Q2: Is Alkacel given as a drip or an injection?

Alkacel 50 mg/1 mL is supplied as an injectable melphalan formulation that must be diluted and given intravenously in hospital. Depending on the protocol, it may be infused over a defined period through a central or peripheral line. It is not intended for intramuscular injection or self-administration at home.

Q3: Will I lose my hair with Alkacel?

Hair thinning or hair loss can occur with melphalan, particularly when it is used at higher doses or in combination with other chemotherapies. Not every patient loses all hair, and regrowth usually occurs after treatment finishes, although timing varies. Your oncology team can give you a more precise estimate based on your overall regimen.

Q4: How will my doctors monitor me during Alkacel treatment?

During Alkacel therapy you will have regular blood tests to monitor blood counts, kidney and liver function, as well as clinical assessments to check for infections, bleeding, gastrointestinal symptoms and other side effects. In the transplant setting, monitoring is particularly intensive, with daily reviews until blood counts recover and complications are under control.

Q5: Can Alkacel be substituted with oral melphalan tablets?

Oral melphalan and injectable melphalan have different dosing, absorption and stability characteristics. Substitution between Alkacel injection and oral melphalan tablets is not a simple milligram-for-milligram switch and must only be done by specialists using validated protocols. You should not change formulation or brand on your own; any adjustments must be made by your haematology team.